About

We are a clinical stage oncology company leveraging our unique precision medicine platform, called Acrivon Predictive Precision Proteomics (AP3), for development of our drug pipeline. AP3 is used to generate proprietary OncoSignature companion diagnostics to identify the patients who will benefit from our medicines. The name Acrivon (derived from Greek for “accurate”) embodies how our OncoSignature tests link the patient’s active tumor-driving mechanisms with the drug’s mode-of-action to accurately match our therapies with patients who will benefit independent of underlying genetic tumor alterations. Our pipeline includes the advanced Phase 2 lead program, ACR-368 (prexasertib), a clinically active CHK1/2 inhibitor, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its co-crystallography-driven, internally developed pipeline programs, consisting of its clinical candidate, ACR-2316, a selective, dual WEE1/PKMYT1 inhibitor, and a preclinical cell cycle program with an undisclosed target.